Welcome to our dedicated page for Covista SEC filings (Ticker: CVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Covista Inc. filings document current reports on operating results, academic performance, investor communications and strategic progress for its healthcare education portfolio. Recent Form 8-K records furnish quarterly results releases, enrollment metrics, revenue and earnings measures, fiscal guidance, share repurchase activity, debt refinancing references and institutional updates for Chamberlain and Walden.
The company's Regulation FD disclosures also include investor newsletters describing milestones, partnerships, workforce-related initiatives and operational progress. Covista's filing record identifies public-company disclosure themes tied to results of operations, capital allocation, governance signatories, cautionary forward-looking statements and the company's current identity as a NYSE-listed healthcare educator.
Covista Inc. lead independent director Michael W. Malafronte reported open-market purchases of a total of 36,036 shares of Covista common stock. The trades were executed on March 10 and 11 at weighted average prices around $100.9 per share.
One purchase of 11,841 shares on March 10 was held directly, leaving 113,205 directly held shares after that trade. Two additional purchases of 15,305 and 8,890 shares were made for the Michael W Malafronte 2016 Gift Trust, an irrevocable trust for which he serves as trustee, bringing that trust’s reported holdings to 25,395 shares after the March 11 transaction.